Order Article Reprints

Marković F, Hochmair M, Müser N, Fabikan H, Rodriguez VM, Janzic U, Stjepanović M, Kontić M. The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study. Cancers. 2025; 17(13):2190. https://doi.org/10.3390/cancers17132190

Marković, Filip, Maximilian Hochmair, Nino Müser, Hannah Fabikan, Vania Mikaela Rodriguez, Urska Janzic, Mihailo Stjepanović, and Milica Kontić. 2025. "The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study" Cancers 17, no. 13: 2190. https://doi.org/10.3390/cancers17132190

Marković, F., Hochmair, M., Müser, N., Fabikan, H., Rodriguez, V. M., Janzic, U., Stjepanović, M., & Kontić, M. (2025). The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study. Cancers, 17(13), 2190. https://doi.org/10.3390/cancers17132190